Escitalopram

is prescribed to treat:

• Depression and generalized anxiety disorder • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Escitalopram (Lexapro) is a selective serotonin reuptake inhibitor used for major depressive disorder and generalized anxiety disorder. It is the S-enantiomer of citalopram — the pharmacologically active half of that racemic drug — and it is among the most commonly chosen first-line antidepressants because it combines good tolerability with the fewest drug interactions in the class.

Mechanism of Action

Escitalopram blocks the presynaptic serotonin transporter, reducing reuptake of serotonin and increasing its availability in the synapse. It is the most selective SSRI available, with negligible activity at norepinephrine and dopamine transporters and minimal affinity for histaminic, muscarinic, or adrenergic receptors — which is the pharmacologic basis of its relatively clean side-effect profile compared with older antidepressants.

Citalopram is a racemic mixture of R- and S-enantiomers, of which only the S form meaningfully inhibits the transporter; the R form may actually interfere with it. Escitalopram is therefore roughly twice as potent per milligram, and its dose range is correspondingly half that of citalopram.

As with all SSRIs, transporter blockade is immediate while clinical benefit takes two to six weeks. The therapeutic effect is attributed to downstream adaptation — receptor desensitisation, altered gene expression, changes in neuroplasticity — rather than the acute rise in synaptic serotonin. The practical consequence is unchanged across the class and worth stating plainly to every patient at the outset: side effects arrive before benefit does, and most people who quit do so in exactly that window.

Clinical Use

Escitalopram is a reasonable first-line agent for depression and for generalized anxiety, and it is also used in panic disorder and social anxiety. In anxiety disorders, starting at a lower dose than one would for depression reduces the initial jitteriness and symptom amplification that can otherwise convince an anxious patient the drug is making things worse.

Its main practical advantage is metabolic: escitalopram is a weak inhibitor of CYP enzymes, so it interacts with far fewer drugs than fluoxetine or paroxetine. In a patient on several medications — particularly one taking metoprolol, tamoxifen, or another CYP2D6 substrate — that matters more than any efficacy difference between SSRIs, which is small.

An adequate trial means an adequate dose for at least four to six weeks. Concluding failure earlier, or at a subtherapeutic dose, is the most frequent error in antidepressant prescribing. Sexual dysfunction is the most common persistent side effect and the most common unspoken reason for discontinuation; asking directly rather than waiting for the patient to raise it allows for dose reduction, a switch to bupropion or mirtazapine, or augmentation. The St. Pete mental health guide covers local options, and our psychiatric team coordinates medication with therapy referral, since the combination outperforms either alone in moderate-to-severe illness.

Monitoring and Follow-Up

Follow up within one to two weeks of starting, particularly in younger patients, then at four to six weeks to judge response. Standardised instruments such as the PHQ-9 or GAD-7 make partial response visible in a way that clinical impression does not, and partial response is the situation that most often needs a decision rather than more time.

Escitalopram, like citalopram, prolongs the QT interval in a dose-dependent way, and this is its one class-atypical monitoring consideration. Maximum doses are lower in older adults and in hepatic impairment for this reason. An ECG is worth obtaining in patients with known cardiac disease, electrolyte abnormalities, or concurrent QT-prolonging drugs, and potassium and magnesium should be repleted where low. The MedlinePlus escitalopram entry covers the prescribing detail.

Sodium deserves attention in older adults, since SSRIs cause hyponatremia through SIADH — typically within the first weeks and presenting as confusion, unsteadiness, or falls rather than anything obviously chemical. Checking sodium a few weeks after starting is prudent in elderly patients and those on diuretics.

After response, continue for at least six to twelve months following remission of a first episode, and longer with recurrent illness, because stopping early is a common cause of relapse. When discontinuation is appropriate, taper gradually; the SSRI discontinuation article explains how to distinguish withdrawal from returning illness, a distinction that changes the decision entirely. The National Institute of Mental Health provides patient-level background on what treatment should look like.

Special Populations

Antidepressants carry a boxed warning about increased suicidal thinking in patients under 25 during early treatment, which calls for closer follow-up in the first weeks rather than avoidance — untreated depression carries substantial risk of its own.

In older adults, the maximum dose is reduced because of QT prolongation, and hyponatremia, falls, and bleeding risk all warrant attention. In pregnancy, SSRIs are used when the illness warrants it; sertraline has the largest accumulated dataset, but escitalopram is used and the decision weighs medication exposure against the well-documented harms of untreated perinatal depression. Hepatic impairment requires dose reduction. Escitalopram is contraindicated within two weeks of an MAO inhibitor, and combining it with other serotonergic agents — triptans, tramadol, linezolid, St. John's wort — raises serotonin syndrome risk.

Switching between SSRIs is common and generally straightforward, since cross-tapering within the class avoids both discontinuation symptoms and a gap in treatment. What is less often explained is that a poor response to one SSRI does not predict a poor response to another; differences between individuals are far larger than differences between the drugs, and a patient who failed one agent has a reasonable chance with a second. That is a more productive framing than concluding after a single trial that antidepressants do not work for them, which is a common and consequential misreading of a first failure.

When to Contact Your Doctor

Seek urgent care for agitation with fever, rapid heart rate, muscle rigidity or twitching, sweating, and confusion, which together suggest serotonin syndrome. Report palpitations, fainting, or near-fainting, given the QT effect. Contact your clinician promptly for new or worsening thoughts of self-harm, marked agitation, or a switch into unusually elevated mood or reduced need for sleep, which may indicate an underlying bipolar diathesis. Confusion, marked unsteadiness, or falls warrant a sodium check. Do not stop escitalopram abruptly.

To review whether your dose is adequate, discuss side effects, or plan a safe taper, contact us or schedule a visit.